179 related articles for article (PubMed ID: 38672174)
1. Analysing the Combined Effects of Radiotherapy and Chemokine Receptor 5 Antagonism: Complementary Approaches to Promote T Cell Function and Migration in Oesophageal Adenocarcinoma.
Davern M; O' Donovan C; Donlon NE; Mylod E; Gaughan C; Bhardwaj A; Sheppard AD; Bracken-Clarke D; Butler C; Ravi N; Donohoe CL; Reynolds JV; Lysaght J; Conroy MJ
Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672174
[TBL] [Abstract][Full Text] [Related]
2. Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma.
Donlon NE; Davern M; O'Connell F; Sheppard A; Heeran A; Bhardwaj A; Butler C; Narayanasamy R; Donohoe C; Phelan JJ; Lynam-Lennon N; Dunne MR; Maher S; O'Sullivan J; Reynolds JV; Lysaght J
World J Gastroenterol; 2022 Jun; 28(21):2302-2319. PubMed ID: 35800186
[TBL] [Abstract][Full Text] [Related]
3. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.
Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; McGrath J; Sheppard AD; Hayes C; King R; Temperley H; MacLean M; Bulter C; Bhardwaj A; Moore J; Donohoe C; Ravi N; Conroy MJ; Reynolds JV; Lysaght J
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5377-5395. PubMed ID: 36445478
[TBL] [Abstract][Full Text] [Related]
4. The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank.
Lonie JM; Brosda S; Bonazzi VF; Aoude LG; Patel K; Brown I; Sharma S; Lampe G; Addala V; Koufariotis LT; Wood S; Waddell N; Dolcetti R; Barbour AP
Front Immunol; 2023; 14():1220129. PubMed ID: 37965317
[TBL] [Abstract][Full Text] [Related]
5. Altered T Cell Migratory Capacity in the Progression from Barrett Oesophagus to Oesophageal Adenocarcinoma.
Kavanagh ME; Conroy MJ; Clarke NE; Gilmartin NT; Feighery R; MacCarthy F; O'Toole D; Ravi N; Reynolds JV; O' Sullivan J; Lysaght J
Cancer Microenviron; 2019 Apr; 12(1):57-66. PubMed ID: 30834503
[TBL] [Abstract][Full Text] [Related]
6. Mucosal-Associated Invariant T Cells Display Diminished Effector Capacity in Oesophageal Adenocarcinoma.
Melo AM; O'Brien AM; Phelan JJ; Kennedy SA; Wood NAW; Veerapen N; Besra GS; Clarke NE; Foley EK; Ravi A; MacCarthy F; O'Toole D; Ravi N; Reynolds JV; Conroy MJ; Hogan AE; O'Sullivan J; Dunne MR
Front Immunol; 2019; 10():1580. PubMed ID: 31354725
[TBL] [Abstract][Full Text] [Related]
7. The Omentum in Obesity-Associated Cancer: A Hindrance to Effective Natural Killer Cell Migration towards Tumour Which Can Be Overcome by CX3CR1 Antagonism.
Mylod E; O'Connell F; Donlon NE; Butler C; Reynolds JV; Lysaght J; Conroy MJ
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008227
[TBL] [Abstract][Full Text] [Related]
8. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.
Berghuis D; Santos SJ; Baelde HJ; Taminiau AH; Egeler RM; Schilham MW; Hogendoorn PC; Lankester AC
J Pathol; 2011 Feb; 223(3):347-57. PubMed ID: 21171080
[TBL] [Abstract][Full Text] [Related]
9. In vitro effects of the CCR5 inhibitor maraviroc on human T cell function.
Arberas H; Guardo AC; Bargalló ME; Maleno MJ; Calvo M; Blanco JL; García F; Gatell JM; Plana M
J Antimicrob Chemother; 2013 Mar; 68(3):577-86. PubMed ID: 23152485
[TBL] [Abstract][Full Text] [Related]
10. Chemokine receptor CCR5 correlates with functional CD8
Wang X; Russell-Lodrigue KE; Ratterree MS; Veazey RS; Xu H
FASEB J; 2019 Aug; 33(8):8905-8912. PubMed ID: 31034775
[TBL] [Abstract][Full Text] [Related]
11. Acidosis significantly alters immune checkpoint expression profiles of T cells from oesophageal adenocarcinoma patients.
Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; Habash M; Sheppard AD; MacLean M; Dunne MR; Moore J; Temperley H; Conroy MJ; Butler C; Bhardwaj A; Ravi N; Donohoe CL; Reynolds JV; Lysaght J
Cancer Immunol Immunother; 2023 Jan; 72(1):55-71. PubMed ID: 35708739
[TBL] [Abstract][Full Text] [Related]
12. Real-time ex vivo monitoring of NK cell migration toward obesity-associated oesophageal adenocarcinoma following modulation of CX3CR1.
Mylod E; O'Connell F; Donlon NE; Davern M; Marion C; Butler C; Reynolds JV; Lysaght J; Conroy MJ
Sci Rep; 2024 Feb; 14(1):4017. PubMed ID: 38369570
[TBL] [Abstract][Full Text] [Related]
13. C-C chemokine receptor 5 and acute graft-versus-host disease.
Yuan J; Ren HY
Immun Inflamm Dis; 2022 Sep; 10(9):e687. PubMed ID: 36039647
[TBL] [Abstract][Full Text] [Related]
14. Potential of damage associated molecular patterns in synergising radiation and the immune response in oesophageal cancer.
Donlon NE; Davern M; Sheppard A; O'Connell F; Moran B; Nugent TS; Heeran A; Phelan JJ; Bhardwaj A; Butler C; Ravi N; Donohoe CL; Lynam-Lennon N; Maher S; Reynolds JV; Lysaght J
World J Gastrointest Oncol; 2023 Aug; 15(8):1349-1365. PubMed ID: 37663943
[TBL] [Abstract][Full Text] [Related]
15. CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth.
Casagrande N; Borghese C; Visser L; Mongiat M; Colombatti A; Aldinucci D
Haematologica; 2019 Mar; 104(3):564-575. PubMed ID: 30309853
[TBL] [Abstract][Full Text] [Related]
16. The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density.
Desmetz C; Lin YL; Mettling C; Portalès P; Rabesandratana H; Clot J; Corbeau P
Immunology; 2006 Dec; 119(4):551-61. PubMed ID: 17177831
[TBL] [Abstract][Full Text] [Related]
17. In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells.
Rossi R; Lichtner M; De Rosa A; Sauzullo I; Mengoni F; Massetti AP; Mastroianni CM; Vullo V
Clin Exp Immunol; 2011 Nov; 166(2):184-90. PubMed ID: 21985364
[TBL] [Abstract][Full Text] [Related]
18. CCR1 antagonism attenuates T cell trafficking to omentum and liver in obesity-associated cancer.
Conroy MJ; Galvin KC; Kavanagh ME; Mongan AM; Doyle SL; Gilmartin N; O'Farrelly C; Reynolds JV; Lysaght J
Immunol Cell Biol; 2016 Jul; 94(6):531-7. PubMed ID: 27046081
[TBL] [Abstract][Full Text] [Related]
19. Visceral Adipose Tissue Modulates Radiosensitivity in Oesophageal Adenocarcinoma.
Mongan AM; Lynam-Lennon N; Doyle SL; Casey R; Carr E; Cannon A; Conroy MJ; Pidgeon GP; Brennan L; Lysaght J; Reynolds JV; O'Sullivan J
Int J Med Sci; 2019; 16(4):519-528. PubMed ID: 31171903
[TBL] [Abstract][Full Text] [Related]
20. Real-time metabolic profiling of oesophageal tumours reveals an altered metabolic phenotype to different oxygen tensions and to treatment with Pyrazinib.
Buckley AM; Dunne MR; Morrissey ME; Kennedy SA; Nolan A; Davern M; Foley EK; Clarke N; Lysaght J; Ravi N; O'Toole D; MacCarthy F; Reynolds JV; Kennedy BN; O'Sullivan J
Sci Rep; 2020 Jul; 10(1):12105. PubMed ID: 32694701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
